- Johnson & Johnson's TREMFYA (guselkumab) significantly reduced joint structural damage in active psoriatic arthritis per Phase 3b APEX study.
- TREMFYA-treated patients showed superior efficacy in key metrics, achieving better outcomes in joint damage inhibition and disease activity measures than placebo.
- TREMFYA demonstrated a consistent safety profile with no new concerns identified, reinforcing its potential as a leading treatment for psoriatic arthritis.
Johnson & Johnson has announced breakthrough findings from its Phase 3b APEX study, demonstrating the efficacy of TREMFYA (guselkumab) in treating active psoriatic arthritis (PsA). The study reveals that TREMFYA significantly inhibits the progression of joint structural damage, a crucial factor in managing PsA. Patients treated with TREMFYA showed a mean vdH-S score change of 0.55 (Q4W) and 0.54 (Q8W), compared to 1.35 for the placebo group, showcasing approximately two and a half times greater protection against joint damage.
In terms of disease activity measures, the results are equally impressive. About 67-68% of TREMFYA-treated patients achieved ACR20 responses, compared to 47% in the placebo group. Furthermore, more than twice as many patients (41-42%) reached ACR50, a measure of significant clinical response, compared to only 20% of placebo patients. TREMFYA also achieved notable skin clearance results, with 68-73% of patients having clear or almost clear skin (IGA score 0/1) versus 31% for placebo.
The APEX study underlines TREMFYA's position as the only IL-23 inhibitor proven to significantly inhibit structural damage in PsA. This data strengthens TREMFYA's standing among treatments for PsA, offering an innovative option that combines efficacy in preventing joint damage with a solid safety profile. With no new safety signals identified, TREMFYA continues to be a safe treatment option for PsA, potentially altering the therapeutic landscape for patients afflicted by this chronic inflammatory condition.
